Skip to main content
. Author manuscript; available in PMC: 2016 Jul 27.
Published in final edited form as: Mucosal Immunol. 2016 Jan 27;9(3):821–833. doi: 10.1038/mi.2015.145

Figure 2. Plasma HIV-1-specific IgG and IgA are frequently detected in HIV-1-infected women participating in the CAPRISA 004 microbicide trial.

Figure 2

Plasma HIV-1 IgG (a–e) and HIV-1 IgA (f–j) to gp70 V1V2, gp120, V3, Gag and p66 antigens were measured in HIV-1-infected CAPRISA 004 participants from 3 to 39 months post infection. Solid lines represent participants in the tenofovir arm and dotted lines represent participants in the placebo arm. In parentheses below are the sample sizes for each time point. Asterisks indicate significant differences in detection between the arms at respective timepoints (Fisher’s exact test).